Virginia De Cesare
University of Dundee, MRC Protein Phosphorylation and Ubiquitylation Unit
Papers
2
Total Citations
55
H-Index
2
About
Dr. Virginia De Cesare is a leading figure in the development of high-throughput screening technologies for drug discovery, with a specialized focus on deubiquitylating enzymes (DUBs). Her work centers on leveraging matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry to create robust, label-free assays that accelerate the identification of novel therapeutic compounds. Her seminal 2020 paper, "High-throughput matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry–based deubiquitylating enzyme assay for drug discovery," has garnered 49 citations, establishing a foundational methodology for the field. This work, further refined in a 2022 publication, demonstrates her commitment to advancing assay sensitivity and throughput, enabling researchers to screen large chemical libraries against DUBs—key regulators of protein degradation and signaling pathways implicated in cancer and neurodegenerative diseases. Dr. De Cesare’s contributions provide a critical tool for bridging basic ubiquitin biology with translational drug development, making her a pivotal innovator in mass spectrometry-based assay design. Her research continues to shape how the pharmaceutical industry approaches DUB-targeted therapies.
Research Focus
Key Achievements
Top Papers
- 1
- 2